Abstracts tagged "anti-CCP antibodies"

Abstract Number: 2212 • 2015 ACR/ARHP Annual Meeting
Identification of a Novel Chemokine-Dependent Molecular Mechanism Underlying Rheumatoid Arthritis-Associated Autoantibody-Mediated Bone Destruction
Akilan Krishnamurthy¹, Vijay Joshua², Aase Haj Hensvold³, Tao Jin⁴, Meng Sun³, Marianne Engström³, Khaled Amara¹, Malin MAgnusson⁴, Camilla Svensson⁵, Vivianne Malmström³, L. Klareskog¹, Heidi Wähämaa³ and Anca I Catrina³, ¹Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, Gothenberg, Sweden, ⁵Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA)-specific anti-citrullinated protein/peptide antibodies (ACPAs) appear before disease onset and are associated with bone destruction. We aimed to dissect the role of…
Abstract Number: 447 • 2015 ACR/ARHP Annual Meeting
Components of Treatment Delay in Rheumatoid Arthritis Differ According to Autoantibody Status
Arthur G Pratt¹, Ben Hargreaves², Dennis W Lendrem², Osman Aslam² and John D Isaacs², ¹Institute of Cellular Medicine (Musculoskeletal Research Group), National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Despite a proliferation of early arthritis (EA) clinics intended to expedite the diagnosis of rheumatoid arthritis (RA), patients continue to experience substantial and multifactorial…
Abstract Number: 2213 • 2015 ACR/ARHP Annual Meeting
RA-Associated Autoantibodies Promote Synovial Fibroblasts Migration and Adhesion through a Peptidylarginine Deiminases (PAD) Dependent Pathway
Meng Sun¹, Vijay Joshua², Aase Haj Hensvold^1,3, Khaled Amara⁴, Vivianne Malmström¹, Heidi Wähämaa¹ and Anca I Catrina¹, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The presence of anti-citrullinated proteins antibodies (ACPAs) in RA is associated with a more aggressive disease phenotype and bone destruction. Synovial fibroblasts (SFs) are…
Abstract Number: 479 • 2015 ACR/ARHP Annual Meeting
How to Recruit Anti-CCP Positive Patients from Primary Care
Jackie L. Nam¹, Laura Hunt¹, Elizabeth M.A. Hensor¹ and Paul Emery^1,2, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom
Background/Purpose: Around 1% of the population test positive for anti-cyclic citrullinated peptide (anti-CCP) antibodies. This biomarker predicts progression to rheumatoid arthritis (RA) but over a…
Abstract Number: 2372 • 2015 ACR/ARHP Annual Meeting
Timing of Onset and Cluster with Other Manifestations Influence the Spectrum of Arthritis in Anti Jo-1 Positive Antisynthetase Syndrome: Results from a Multicenter, International, Retrospective Study
Alberto Sifuentes Giraldo¹, Carlo Alberto Scirè², Santos Castañeda³, Laura Nuño⁴, Francisco Javier Lopez Longo⁵, Julia Martínez-Barrio⁵, Franco Franceschini⁶, Ilaria Cavazzana⁶, Paolo Airò⁷, Elena Bartoloni Bocci⁸, Javier Bachiller Corral⁹, Rossella Neri¹⁰, Simone Barsotti¹¹, Roberto Caporali¹², Carlomaurizio Montecucco¹³, Marcello Govoni¹⁴, Renato La Corte¹⁴, Federica Furini¹⁴, Florenzo Iannone¹⁵, Margherita Giannini¹⁶, Enrico Fusaro¹⁷, Simone Parisi¹⁸, Giuseppe Paolazzi¹⁹, Giovanni Barausse¹⁹, Raffaele Pellerito²⁰, Alessandra Russo²⁰, Lesley Ann Saketkoo²¹, Norberto Ortego-Centeno²², Luca Quartuccio²³, Christof Specker²⁴, Andreas Schwarting²⁵, Kostantinos Triantafyllias²⁶, Carlo Selmi²⁷, Fausto Salaffi²⁸, Marco Amedeo Cimmino²⁹, Annamaria Iuliano³⁰, Fabrizio Conti³¹, Gianluigi Baiocchi³², Elena Bravi³³, Veronica Codullo¹², Anna Ghirardello³⁴, Trinitario Pina³⁵, Miguel Angel Gonzalez-Gay³⁵, Lorenzo Cavagna¹³ and AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group, ¹Department of Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ²Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, ³Rheumatology, H.U. La Princesa, Madrid, Spain, ⁴Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Spain, ⁵Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁷Rheumatology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁸Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy, ⁹Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ¹⁰Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹¹Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹²Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ¹³Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ¹⁴UOC Reumatologia, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy, ¹⁵Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ¹⁶DIM, Rheumatology Unit, Bari, Italy, ¹⁷Department of Rheumatology, Città della Salute e della Scienza, Torino, Italy, ¹⁸Department of Rheumatology, Città Della Salute e della Scienza, Torino, Italy, ¹⁹Rheumatology Unit, Santa Chiara Hospital, Trento, Italy, ²⁰Division of Rheumatology, Mauriziano Hospital, Turin, Italy, ²¹Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²²Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain, ²³Clinic of Rheumatology, Department of Medical and Biological Sciences (DSMB), Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ²⁴Department for Rheumatology and Clinical Immunology, St. Josef Krankenhaus, University Clinic, Essen, Germany, ²⁵Department of Internal Medicine, Rheumatology and Clinical Immunology, University Hospital Johannes-Gutenberg, Mainz, Germany, ²⁶ACURA Rheumatology Center, Bad Kreuznach, Germany, ²⁷Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, ²⁸Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ²⁹Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy, ³⁰Osp. San Camillo, Roma, Italy, ³¹Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ³²Rheumatology Unit, Department of Internal Medicine, S.Maria Hospital –IRCCS, Reggio Emilia, Italy, ³³Internal Medicine, Rheumatology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy, ³⁴Department of Medicine-DIMED, University of Padova, Padova, Italy, ³⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: arthritis, myositis and interstitial lung disease (ILD) are reported in up to 90% of patients affected by antisynthetase syndrome (ASSD) and thus represent the…
Abstract Number: 2921 • 2014 ACR/ARHP Annual Meeting
Contraceptive Factors Are Associated with Serum Antibodies to Citrullinated Protein Antigens in Women at Elevated Risk for Future Rheumatoid Arthritis
Sonia Khatter¹, Mark C. Parish², Marie L. Feser², Jason R. Kolfenbach², Ryan W. Gan³, Michael H. Weisman⁴, James R. O'Dell⁵, Ted R. Mikuls⁶, Richard M. Keating⁷, Peter K. Gregersen⁸, Jane H. Buckner⁹, V. Michael Holers¹⁰, Kevin D. Deane², Jill M. Norris³ and M. Kristen Demoruelle², ¹University of Colorado School of Medicine, Aurora, CO, ²Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ³Epidemiology, Colorado School of Public Health, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology, Scripps Clinic, La Jolla, CA, ⁸Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹⁰Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: The preclinical period of rheumatoid arthritis (RA) development is characterized by elevations of serum RA-related autoantibodies (Abs) including Abs to citrullinated protein antigens (ACPA)…
Abstract Number: 1404 • 2014 ACR/ARHP Annual Meeting
Presence and Significance of Anti-CCP Antibody in Patients with Interstitial Lung Disease with and without Clinically Apparent Rheumatoid Arthritis
Muhammad Imran¹, Shanley O'brien², Mark Hamblin³ and Mehrdad Maz⁴, ¹Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Internal Medicine, Kansas University Medical Center, Kansas city, MO, ³Pulmonary and Critical Care Medicine, ILD Clinic, Kansas University Medical Center, Kansas city, MO, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Interstitial lung disease (ILD) can be idiopathic or associated with underlying etiologies including rheumatoid arthritis (RA). The purpose of this study is to determine…
Abstract Number: 1377 • 2014 ACR/ARHP Annual Meeting
Anti-Citrullinated Peptide Antibody Titers and the Prevalence of Interstitial Lung Disease in Patients with and without Rheumatoid Arthritis
Chase Correia¹, Melissa R. Bussey², Brittany Panico¹, Rong Guo³ and Rochella A. Ostrowski⁴, ¹Internal Medicine, Loyola University Medical Center, Chicago, IL, ²Rheumatology, Division of Rheumatology, Loyola University Medical Center, Maywood, IL, ³Loyola University Medical Center, Chicago, IL, ⁴Rheumatology, Loyola University Medical Center, Maywood, IL
Background/Purpose: Rheumatoid arthritis (RA) is a multisystem inflammatory disease characterized by a symmetric, destructive polyarthritis. Interstitial lung disease (ILD) is an extra-articular manifestation that…
Abstract Number: 1039 • 2014 ACR/ARHP Annual Meeting
Interleukin-20 Is Triggered By TLR Ligands and Associates with Rheumatoid Arthritis Disease Activity
Ladislav Senolt¹, Klara Prajzlerova¹, Hana Hulejova², David Veigl³, Karel Pavelka¹ and Jiri Vencovsky¹, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³1st Orthopaedic Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation and subsequent joint damage with systemic manifestations. Interleukin-20 (IL-20) has been…
Abstract Number: 388 • 2014 ACR/ARHP Annual Meeting
Soluble TREM-1 Is a Biomarker of Anti-CCP-Positive, DMARD-Naive Early Rheumatoid Arthritis
Shachaf Ofer-Shiber¹, Elisheva Pokroy-Shapira², Yair Molad^3,4, Shirly Oren², Hagit Shay-Aharoni² and Ilan Babai⁵, ¹Department of Internal Medicine H, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ²Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ³Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petah Teqva, Israel, ⁴Laboratory of Inflammation Research, Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ⁵Laboratory of Clinical Immunology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
Background/Purpose : Triggering receptor expressed on myeloid cells-1 (TREM-1) is a cell-surface receptor, expressed mainly on monocytes and neutrophils and involved in amplification of the inflammatory…
Abstract Number: 380 • 2014 ACR/ARHP Annual Meeting
In Palindromic Rheumatism, Older Age, Shorter Interval Between Attacks and Positive Anti-CCP Antibodies May Predict Progression to RA
Masatoshi Hayashi^1,2, Jackie L. Nam³, Laura Hunt³, Elizabeth Hensor³, Toshihisa Kanamono⁴, Toshihisa Kojima⁵, Naoki Ishiguro⁵ and Paul Emery⁶, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., Leeds, United Kingdom, ²5-22-1 Wakasato, Nagano Red Cross Hospital, Nagano, Japan, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ⁵Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁶NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., United Kingdom, Leeds, United Kingdom
Background/Purpose Palindromic rheumatism (PR) is a clinical syndrome characterised by episodes of joint swelling that settle spontaneously. A proportion of patients with PR progress and…
Abstract Number: 371 • 2014 ACR/ARHP Annual Meeting
The Impact of Missing Anti-Citrullinated Protein Antibody (ACPA) on Outcomes in Early Rheumatoid Arthritis: From the Canadian Early Arthritis Cohort
Jenny Shu¹, Vivian P. Bykerk², Gilles Boire³, Carol A. Hitchon⁴, J. Carter Thorne⁵, Diane Tin⁶, Edward C. Keystone⁷, Boulos Haraoui⁸ and Janet E. Pope⁹, ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁴Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Medicine, University of Toronto, Toronto, ON, Canada, ⁸Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁹St Joseph Health Care, London, ON, Canada
Background/Purpose: The impact of missing ACPA in early inflammatory arthritis patients was studied to determine if failure to perform ACPA testing could cause a care…
Abstract Number: 124 • 2014 ACR/ARHP Annual Meeting
Ultrasound Power Doppler Findings in the Wrists and Hands Joints of Anti-CCP Antibody Positive Individuals with Non-Specific Musculoskeletal Symptoms and the Development of Inflammatory Arthritis
Jackie L. Nam, Laura Hunt, Elizabeth M.A. Hensor, Philip G. Conaghan, Richard J. Wakefield and Paul Emery, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose The use of musculoskeletal ultrasound is increasing in rheumatology practice. Recently we have shown that use of power Doppler signal (PD) on ultrasound in…
Abstract Number: 1309 • 2013 ACR/ARHP Annual Meeting
Prognosis Of Seronegative Patients In a Large Prospective Cohort Of Patients With Early Inflammatory Arthritis
Lillian J. Barra¹, Janet E. Pope², Boulos Haraoui³, Carol A. Hitchon⁴, J. Carter Thorne⁵, Edward C. Keystone^6,7, Diane Tin⁸, Gilles Boire⁹ and Vivian P. Bykerk¹⁰, ¹Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ³Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁴Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Rheumatoid Factor (RF) and anti-Cyclic Citrullinated Peptide (anti-CCP) are believed to be associated with more severe clinical outcomes; however, studies in Early Inflammatory Arthritis…
Abstract Number: 808 • 2013 ACR/ARHP Annual Meeting
A Genome Wide Association Study Of Rheumatoid Arthritis Without Antibodies Against Citrullinated Peptides
Lara Bossini-Castillo¹, Carolien de Kovel², Henrik Kallberg³, Marieke J.H. Coenen⁴, Paul P. Tak⁵, Marcel D. Posthumus⁶, Cisca Wijmenga⁷, Thomas W.J. Huizinga⁸, Annette H.M. van der Helm-van Mil⁹, Luis Rodriguez-Rodriguez¹⁰, Isidoro Gonzalez-Alvaro¹¹, Miguel Angel Gonzalez-Gay¹², Irene E. van der Horst-Bruinsma¹³, B.a.C Dijkmans¹⁴, G. J. Wolbink¹⁵, Roel A. Ophoff², Piet L.C.M. van Riel¹⁶, Lars Klareskog³, J.B.a. Crusius¹⁷, Elisabeth Brouwer¹⁸, Javier Martin¹⁹, Niek de Vries⁵, René E.M. Toes⁹, Leonid Padyukov²⁰ and Bobby P.C. Koeleman²¹, ¹Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ²Department of Medical Genetics, UMCU Utrecht, Utrecht, Netherlands, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁶Department of Rheumatology, University of Groningen, University Medical Center, Groningen, Netherlands, ⁷Department of Genetics, University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁰Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, ¹¹Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, ¹²Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander, Santander, Spain, ¹³Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ¹⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ¹⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ¹⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁷Pathology, VU University Medical Center, Amsterdam, Netherlands, ¹⁸Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ¹⁹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ²⁰Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²¹Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease that is associated with a progressive loss of the joints induced by a chronic inflammation of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].